目的 探討康婦炎膠囊聯(lián)合阿奇霉素治療慢性盆腔炎的臨床效果。方法 選取2016年1月—2017年10月溫縣人民醫(yī)院收治的134例慢性盆腔炎患者，隨機(jī)分為對照組和治療組，每組各67例。對照組口服阿奇霉素片，0.5 g/次，1次/d。治療組在對照組治療基礎(chǔ)上口服康婦炎膠囊，3粒/次，3次/d。兩組均連續(xù)治療21 d。觀察兩組的臨床療效，比較兩組治療前后盆腔包塊直徑、癥狀評分、搏動指數(shù)（PI）、收縮期峰值流速（PSV）、阻力指數(shù)（RI）、白細(xì)胞介素（IL）-1β、IL-10和外周血CD⁴⁺/CD⁸⁺的變化情況。結(jié)果 治療后，對照組和治療組的總有效率分別為79.10%、92.54%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者盆腔包塊直徑顯著縮小，帶下異常評分、腰骶脹痛評分、下腹疼痛評分、總評分、IL-1β均顯著降低，PI、PSV、RI值、IL-10、CD⁴⁺/CD⁸⁺較治療前顯著增加，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；治療后，治療組盆腔包塊直徑、帶下異常評分、腰骶脹痛評分、下腹疼痛評分、總評分、IL-1β均顯著低于對照組，PI、PSV、RI值、IL-10、CD⁴⁺/CD⁸⁺高于對照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 康婦炎膠囊聯(lián)合阿奇霉素治療慢性盆腔炎具有較好的臨床療效，可有效改善患者癥狀，調(diào)節(jié)卵巢血流動力學(xué)狀態(tài)，糾正機(jī)體促炎/抗炎因子失衡，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical effect of Kangfuyan Capsules combined with azithromycin in treatment of chronic pelvic inflammation. Methods Patients (134 cases) with chronic pelvic inflammation in Wenxian County People's Hospital from January 2016 to October 2017 were randomly divided into control (67 cases) and treatment (67 cases) groups. Patients in the control group were po administered with Azithromycin Tablets, 0.5 g/time, once daily. Patients in the treatment group were po administered with Kangfuyan Capsules on the basis of the control group,, three grains/time, three times daily. Patients in two groups were treated for 21 d. After treatment, the clinical efficacy was evaluated, and the pelvic cavity diameter, symptom score, PI, PSV, RI, IL-1β, IL-10, and CD⁴⁺/CD⁸⁺ in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 79.10% and 92.54%, and there were differences between two groups (P < 0.05). After treatment, pelvic cavity diameter in two groups were significantly decreased, and abnormal scores, lumbosacral pain scores, lower abdominal pain scores, total scores, and IL-1β were significantly reduced, but PI, PSV, RI, IL-10, CD⁴⁺/CD⁸⁺ were significantly increased, and there were differences in the same group (P < 0.05). After treatment, pelvic cavity diameter, abnormal scores, lumbosacral pain scores, lower abdominal pain scores, total scores, and IL-1β in the treatment group were lower than those in the control group, but PI, PSV, RI, IL-10, CD⁴⁺/CD⁸⁺ were higher than those in the control group, and there were differences between two groups (P < 0.05). Conclusion Kangfuyan Capsules combined with azithromycin has significant clinical effect in treatment of chronic pelvic inflammation, and can effectively improve the symptoms and regulate the hemodynamic state of the ovary, and also can correct the imbalance of pro-inflammatory/anti-inflammatory factors, which has a certain clinical application value.